CJC-1295 Ipamorelin Dosage Calculator (Blend)
A GHRH analogue and a growth hormone secretagogue premixed in one vial. The FDA's advisory committee voted against both, separately.
Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.
Not approved; advisory committee voted against both components
The Pharmacy Compounding Advisory Committee voted against ipamorelin in October 2024 and against CJC-1295 in December 2024, in both cases for lack of evidence of effectiveness. Neither is on any current FDA list.
No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.
Anti-doping: Prohibited at all times. CJC-1295 falls under WADA class S2.1 and ipamorelin under S2.2.
Key facts
- Half-life
- Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
- Also sold as
- CJC ipamorelin, GH stack
How good is the evidence?
No published study has examined this combination. The individual components have one human study each, both from over two decades ago, neither measuring a clinical outcome.
No study has tested this combination
The evidence for this blend is not the sum of the evidence for its parts, because no published human study has administered the two together. What exists is one 2006 human study of CJC-1295 with DAC, and one 1999 single-dose intravenous pharmacokinetic study of ipamorelin. Both examined one compound at a time, and neither examined this vial.
The rationale usually offered — that a GHRH analogue and a growth hormone secretagogue act on different receptors and therefore complement each other — is a mechanistic argument, not a result. It may be right. Nobody has published the trial that would show it, so any figure describing what the combination does is an extrapolation from two separate single-agent studies, and should be read as one.
Both components were reviewed by the FDA's Pharmacy Compounding Advisory Committee and both were voted against for the 503A bulks list: ipamorelin in October 2024, CJC-1295 in December 2024.
The arithmetic problem a blend creates
A single-peptide vial has one concentration, so one draw volume answers everything. A blend has one shared volume of water and two different masses dissolved in it, which means every draw delivers both components in whatever ratio the vial was filled at — and that ratio is fixed by the manufacturer, not by you.
You cannot adjust one component without adjusting the other. If the ratio in the vial is wrong for what you intended, no volume of water and no syringe mark can correct it; the only lever is buying a different vial. That is the real practical difference between a blend and two separate vials, and it is a stronger argument against blends than anything about the pharmacology.
The calculator above therefore reports both components per draw rather than a single figure, because a single figure would conceal the thing that matters.
Common questions
Sources
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- RegulatorFDA· 2024-10October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
- RegulatorFDA· 2024-12-04PCAC briefing document — substance descriptions and 503A statutory conditions
- RegulatorFDA· 2026-05-14Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- RegulatorWorld Anti-Doping Agency· 2026WADA 2026 Prohibited List
- Published studyJournal of Clinical Endocrinology & Metabolism· 2006Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog
- Published studyPharmaceutical Research· 1999Gobburu JVS et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy men
- RegulatorFDACompounding Risk Alerts